PT2318375E - Imidazole carboxamidas - Google Patents

Imidazole carboxamidas Download PDF

Info

Publication number
PT2318375E
PT2318375E PT09790351T PT09790351T PT2318375E PT 2318375 E PT2318375 E PT 2318375E PT 09790351 T PT09790351 T PT 09790351T PT 09790351 T PT09790351 T PT 09790351T PT 2318375 E PT2318375 E PT 2318375E
Authority
PT
Portugal
Prior art keywords
methyl
compound
trifluoromethyl
mmol
pharmaceutically acceptable
Prior art date
Application number
PT09790351T
Other languages
English (en)
Portuguese (pt)
Inventor
Deyi Zhang
Albert Khilevich
Bin Liu
Daniel Ray Mayhugh
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT2318375E publication Critical patent/PT2318375E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
PT09790351T 2008-07-18 2009-07-14 Imidazole carboxamidas PT2318375E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8177408P 2008-07-18 2008-07-18

Publications (1)

Publication Number Publication Date
PT2318375E true PT2318375E (pt) 2012-10-22

Family

ID=41128155

Family Applications (1)

Application Number Title Priority Date Filing Date
PT09790351T PT2318375E (pt) 2008-07-18 2009-07-14 Imidazole carboxamidas

Country Status (19)

Country Link
US (1) US7754742B2 (enExample)
EP (1) EP2318375B1 (enExample)
JP (1) JP5379227B2 (enExample)
KR (1) KR101287713B1 (enExample)
CN (1) CN102099344B (enExample)
AR (1) AR074631A1 (enExample)
BR (1) BRPI0915977A2 (enExample)
CA (1) CA2731215C (enExample)
CY (1) CY1113315T1 (enExample)
DK (1) DK2318375T3 (enExample)
EA (1) EA018434B1 (enExample)
ES (1) ES2393243T3 (enExample)
HR (1) HRP20120830T1 (enExample)
MX (1) MX2011000611A (enExample)
PL (1) PL2318375T3 (enExample)
PT (1) PT2318375E (enExample)
SI (1) SI2318375T1 (enExample)
TW (1) TW201006801A (enExample)
WO (1) WO2010009062A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
BRPI0816970A2 (pt) 2007-09-14 2015-03-24 Ortho Mcneil Janssen Pharm 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
CN103502218B (zh) * 2011-03-04 2016-08-17 生命科技公司 用于缀合生物分子的化合物和方法
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
KR102000382B1 (ko) 2015-02-03 2019-07-15 화이자 인코포레이티드 신규 시클로프로파벤조푸라닐 피리도피라진디온
US10577332B2 (en) 2015-04-23 2020-03-03 Hoffmann-La Roche Inc. Tetrazole derivatives
CN104788694B (zh) * 2015-04-29 2018-06-08 江苏亚宝绝缘材料股份有限公司 一种超低收缩率的聚酰亚胺薄膜
WO2017060202A1 (en) 2015-10-06 2017-04-13 F. Hoffmann-La Roche Ag Triazole derivatives
EP3411365B1 (en) 2016-02-02 2019-11-20 H. Hoffnabb-La Roche Ag Pyrazol-pyridine derivatives as eaat3 inhibitors
CN109071451B (zh) 2016-05-27 2022-07-15 豪夫迈·罗氏有限公司 作为eaat3抑制剂的吡唑化合物
WO2018069362A1 (en) 2016-10-14 2018-04-19 F. Hoffmann-La Roche Ag Imidazole compounds as eaat3 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3068213D1 (en) 1979-09-05 1984-07-19 Glaxo Group Ltd Phenol derivatives, processes for their preparation and pharmaceutical compositions containing them
US4666928A (en) 1984-08-30 1987-05-19 Merck Frosst Canada, Ind. Propylphenoxy pyridine carboxylates as leukotriene antagonists
DE69210091T2 (de) 1991-05-31 1996-10-02 Sumitomo Pharma Leukotrien-B4-Antagonisten
AU2001234420A1 (en) 2000-02-03 2001-08-14 Eli Lilly And Company Potentiators of glutamate receptors
JP2006502143A (ja) * 2002-08-26 2006-01-19 メルク エンド カムパニー インコーポレーテッド 向代謝型グルタミン酸受容体のアセトフェノン増強因子
CN1993326A (zh) * 2004-07-30 2007-07-04 默克公司 代谢型谷氨酸受体的杂环苯乙酮增效剂
CA2574971A1 (en) 2004-07-30 2006-02-09 Merck & Co., Inc. Indanone potentiators of metabotropic glutamate receptors
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
AU2005299797A1 (en) 2004-10-25 2006-05-04 Merck & Co., Inc. Heterocyclic indanone potentiators of metabotropic glutamate receptors
ATE543807T1 (de) * 2004-11-22 2012-02-15 Lilly Co Eli Verstärker von glutamat-rezeptoren
BRPI0517423A (pt) 2004-12-27 2008-10-07 Astrazeneca Ab composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
JP5031745B2 (ja) 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン

Also Published As

Publication number Publication date
AR074631A1 (es) 2011-02-02
HRP20120830T1 (hr) 2012-11-30
CA2731215C (en) 2013-08-27
EA018434B1 (ru) 2013-07-30
EA201170227A1 (ru) 2011-06-30
CN102099344A (zh) 2011-06-15
EP2318375B1 (en) 2012-09-19
CN102099344B (zh) 2013-10-30
EP2318375A1 (en) 2011-05-11
DK2318375T3 (da) 2012-10-08
KR20110022676A (ko) 2011-03-07
JP5379227B2 (ja) 2013-12-25
JP2011528658A (ja) 2011-11-24
MX2011000611A (es) 2011-03-01
US20100016373A1 (en) 2010-01-21
CY1113315T1 (el) 2016-04-13
WO2010009062A1 (en) 2010-01-21
SI2318375T1 (sl) 2012-11-30
TW201006801A (en) 2010-02-16
US7754742B2 (en) 2010-07-13
KR101287713B1 (ko) 2013-07-23
CA2731215A1 (en) 2010-01-21
AU2009271105A1 (en) 2010-01-21
PL2318375T3 (pl) 2013-02-28
BRPI0915977A2 (pt) 2018-10-30
ES2393243T3 (es) 2012-12-19

Similar Documents

Publication Publication Date Title
ES2393243T3 (es) Imidazol carboxamidas
ES2319107T3 (es) Derivados de 5-halo-triptamina usados como ligandos de los receptores de serotonina 5-ht6 y/o 5-ht7.
TWI837169B (zh) 甲狀腺素受體β促效劑化合物
KR900004384B1 (ko) 복소환식 아미드 유도체 및 그 제조방법
PT701819E (pt) Novas composicoes contendo sertralina e um agonista ou antagonista de receptor de 5-ht1d
CA2642610A1 (en) Amide derivative or salt thereof
CN101679397A (zh) 具有nos抑制活性的喹诺酮、四氢喹啉及其相关化合物
NO326690B1 (no) Nye arylsusfonamidforbindelser for behandlingen av fedme og type II diabetes, fremgangsmåte for fremstilling derav, samt farmasøytiske formuleringer som inneholder slike
JP2006505559A (ja) 5−ht6受容体親和性を持つ4−ピペラジニルベンゼンスルホニルインドール
BR112013000783A2 (pt) derivados arilamídicos tendo propriedades antiandrogênicas
ES2434250T3 (es) Compuestos de 3-(fenoxifenilmetil)pirrolidina
KR900004385B1 (ko) 카복사미드 유도체 및 그의 제조방법
NL1029919C2 (nl) Therapeutische difenyletherliganden.
US20200270214A1 (en) NADPH Oxidase Inhibitors and Uses Thereof
CN108084153A (zh) 吡啶基硫代乙酸化合物、组合物及其应用
JPH11513376A (ja) 選択的β▲下3▼−アドレナリン作動剤
BR112020004419A2 (pt) formas sólidas de 2-(5-(4-(2-morfolinoetóxi)fenil)piridin-2-il)-n-benzilacetamida
JPH02178263A (ja) アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤
JPH06508378A (ja) 新規アミドアルキル−およびイミドアルキル−ピペラジン類
AU2009271105B2 (en) Imidazole carboxamides
TW201623244A (zh) 包含硫基團之4,5-二氫-1h-吡唑-3-甲脒衍生物、其製備方法以及包含其之藥學組成物
US5179112A (en) Heterocyclic amide derivatives and pharmaceutical use
JP2026067759A (ja) C3a受容体拮抗化合物及びその利用
HK40075686A (en) Estrogen receptor-modulating compounds
HK1140754A (en) Quinolone and tetrahydroquinoline and related compounds having nos inhibitory activity